| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
L-Ornithine L-aspartate acts as a substrate for enzymes involved in the urea cycle and glutamine synthesis. Its mechanism of action primarily revolves around its role in ammonia detoxification. Upon administration, it promotes increased synthesis of urea from ammonia. It also enhances mitochondrial function. By increasing ammonia detoxification in muscle and liver, it reduces blood ammonia concentrations.
|
|---|---|
| ln Vitro |
In vitro, L-ornithine L-aspartate is used to study ammonia detoxification and urea cycle function. It serves as a substrate for enzymes in the urea cycle. Its effects on mitochondrial function and glutamine synthesis can be assessed in cell culture models. The compound's ability to reduce ammonia levels is confirmed in hepatocyte or muscle cell cultures.
|
| ln Vivo |
In vivo, L-ornithine L-aspartate effectively lowers blood ammonia concentration by enhancing ammonia detoxification in the muscles. It alleviates hepatic encephalopathy symptoms in liver cirrhosis. It is believed to support liver function and improve the symptoms associated with liver dysfunction. It enhances mitochondrial function, making it valuable for research in liver health.
|
| Enzyme Assay |
In vitro assays for L-ornithine L-aspartate measure its effects on ammonia metabolism. Hepatocyte or muscle cell cultures are treated with the compound, and ammonia levels in the culture medium are measured. Urea production is quantified to assess urea cycle activity. Glutamine synthesis is measured by analyzing glutamine levels. Mitochondrial function is assessed by measuring oxygen consumption rate (OCR) and ATP production.
|
| Cell Assay |
In vitro cellular studies are conducted using hepatocyte or muscle cell lines. Cells are treated with L-ornithine L-aspartate at various concentrations. Ammonia detoxification is assessed by measuring the reduction of ammonia in the culture medium. Urea cycle enzyme activity is measured by quantifying urea production. Glutamine synthetase activity is evaluated. Cell viability and mitochondrial function are assessed using standard assays.
|
| Animal Protocol |
In vivo animal experiments are performed in models of hyperammonemia or hepatic encephalopathy. Animals are administered L-ornithine L-aspartate via oral gavage or injection. Blood ammonia levels are measured at various time points. Liver function tests and neurological assessments are performed to evaluate the compound's efficacy in reducing hepatic encephalopathy symptoms. Liver and muscle tissues are collected for histopathological and biochemical analysis.
|
| ADME/Pharmacokinetics |
L-Ornithine L-aspartate has a molecular formula of C5H12N2O2·C4H7NO4 and a molecular weight of 265.26 g/mol. It is soluble in water (53 mg/mL) but insoluble in DMSO and ethanol. For storage, it should be kept under recommended conditions. The compound is supplied with high purity (100%). It is a stable salt composed of two amino acids.
|
| Toxicity/Toxicokinetics |
As a therapeutic agent, L-ornithine L-aspartate is generally well-tolerated. Common side effects are mild and may include gastrointestinal disturbances. It is contraindicated in patients with hypersensitivity to any of its components. As a research chemical, standard laboratory safety precautions should be followed. The compound is used clinically for the management of hepatic encephalopathy and is not for research use only in that context.
|
| References |
|
| Additional Infomation |
L-Ornithine L-aspartate is also known as LOLA. It is a metabolite of arginine degradation by arginase. The compound has been shown to reduce blood ammonia concentrations by increasing ammonia detoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis. It is used in research on liver health, ammonia metabolism, and hepatic encephalopathy.
|
| Molecular Formula |
C9H19N3O6
|
|---|---|
| Molecular Weight |
265.263662576675
|
| Exact Mass |
265.127
|
| CAS # |
3230-94-2
|
| PubChem CID |
10220941
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
308.7ºC at 760 mmHg
|
| Flash Point |
140.5ºC
|
| LogP |
0.111
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
18
|
| Complexity |
228
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(C[C@@H](C(=O)O)N)CN.C([C@@H](C(=O)O)N)C(=O)O
|
| InChi Key |
IXUZXIMQZIMPSQ-ZBRNBAAYSA-N
|
| InChi Code |
InChI=1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
|
| Chemical Name |
(2S)-2-aminobutanedioic acid;(2S)-2,5-diaminopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~942.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (188.49 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7699 mL | 18.8494 mL | 37.6989 mL | |
| 5 mM | 0.7540 mL | 3.7699 mL | 7.5398 mL | |
| 10 mM | 0.3770 mL | 1.8849 mL | 3.7699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
